免疫检查点抑制剂相关糖尿病:单中心病例系列
该单中心回顾性病例系列分析了18例接受抗PD-1/PD-L1治疗后新发免疫检查点抑制剂相关糖尿病(ICI-DM)的晚期癌症患者。结果显示ICI-DM起病急骤,9例出现糖尿病酮症酸中毒,C肽低且随访中持续下降,影像学可见显著胰腺萎缩。研究提示该病可能不可逆,PD-L1阻断后起病可能早于PD-1抑制,GAD65抗体阳性者起病更早。
要点
- ICI-DM起病急骤,18例中9例以糖尿病酮症酸中毒起病。
- 诊断时C肽中位数低,随访中进一步下降,提示胰岛功能不可逆受损。
- 影像学可见显著胰腺萎缩,PD-L1阻断后起病可能早于PD-1抑制。
核心结论
- ICI-DM起病急骤、似乎不可逆,以胰腺萎缩为特征。
- PD-L1阻断后ICI-DM起病可能早于PD-1抑制,GAD65抗体阳性者起病亦可能更早。
研究设计与样本
- 单中心回顾性病历回顾,纳入18例接受抗PD-1/抗PD-L1治疗晚期癌后新发ICI-DM的患者。
主要发现
- 18例中9例出现糖尿病酮症酸中毒,中位血糖27.92 mmol/L,就诊前中位血糖6.35 mmol/L。
- ICI-DM诊断时C肽中位数低,随访期间下降。
- 抗PD-1/抗PD-L1治疗至ICI-DM的中位时间为3.65个月(范围0.56-12.23个月)。
- GAD65抗体阳性者ICI-DM起病中位时间为1.4个月/3个ICI周期,阴性者为6个月/10个周期。
- 抗PD-L1治疗后者起病中位时间为2.5个月/3个周期,抗PD-1治疗后者为4.8个月/8个周期。
临床怎么用
- 接受抗PD-1/PD-L1治疗的患者应警惕ICI-DM急骤起病,尤其需防范糖尿病酮症酸中毒。
- 监测血糖和C肽有助于早期识别ICI-DM,影像学胰腺萎缩可辅助诊断。
局限性
- 单中心回顾性病例系列,样本量小(18例),无对照组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To characterize immune checkpoint inhibitor-associated diabetes mellitus (ICI-DM) in a single-institution case series. RESEARCH DESIGN AND METHODS: Retrospective chart review of 18 patients with new-onset ICI-DM following anti-programmed cell death protein 1 (PD-1)/anti-programmed cell death protein ligand 1 (PD-L1) therapy for advanced carcinomas. RESULTS: Of 18 patients, 9 had diabetic ketoacidosis (median glucose 27.92 mmol/L; median glucose before presentation 6.35 mmol/L). Median C-peptide at ICI-DM diagnosis was low, and it declined during follow-up. Median anti-PD-1/anti-PD-L1 duration before ICI-DM was 3.65 months (range 0.56-12.23 months). Time to ICI-DM onset was a median 1.4 months/3 ICI cycles and 6 months/10 cycles in those patients who were positive and negative for GAD65 autoantibodies, respectively. Time to ICI-DM onset was a median 2.5 months/3 ICI cycles and 4.8 months/8 cycles after anti-PD-L1 or anti-PD-1 therapy, respectively. Significant pancreatic atrophy was seen radiographically. CONCLUSIONS: ICI-DM presents abruptly, appears irreversible, is characterized by pancreatic atrophy, and may occur both earlier following PD-L1 blockade compared with PD-1 inhibition and in those who have positive GAD65 autoantibodies.
引用
- Byun DJ, Braunstein R, Flynn J, et al. Immune Checkpoint Inhibitor-Associated Diabetes: A Single-Institution Experience. Diabetes Care. 2020. PMID: 33051330. doi:10.2337/dc20-0609
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。